A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens.

TY - JOUR

T1 - A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens.

AU - Castro, Januario E.

AU - Loria, Olivier J.

AU - Aguillon, Robier A.

AU - James, Danelle

AU - Llanos, Cesar A.

AU - Rassenti, Laura

AU - Wood, Brian A.

AU - Homlund, Jon T.

AU - Kipps, Thomas J.

N1 - Januario E. Castro, Olivier J. Loria, Robier A. Aguillon, Danelle James, Cesar A. Llanos, Laura Rassenti, Brian A. Wood, Jon T. Homlund, Thomas J. Kipps; A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens..

PY - 2007/11/16

Y1 - 2007/11/16

UR - https://ashpublications.org/blood/article/110/11/3119/74620/A-Phase-II-Open-Label-Study-of-AT-101-in

U2 - 10.1182/BLOOD.V110.11.3119.3119

DO - 10.1182/BLOOD.V110.11.3119.3119

M3 - Article

VL - 110

JO - Blood

JF - Blood

IS - 11

ER -